3 results
The aim of this phase IVI, randomized, open-label study is to compare the efficacy of cabazitaxel versus an AR targeted agent, in patients previously treated with docetaxel and likely to have primary resistance to AR targeted agents.
Objective: The aim of this study is to evaluate if an adequate level of bowel cleansing can be achieved with the Pure-Vu in patients with previous poor bowel preparation (Boston Bowel Preparation Scale [BBPS]<6).
The primary aim of this study is to examine the feasibility, usability, and acceptability of the educational care pathway for both patients and healthcare professionals. The secondary aim is to investigate the preliminary effects on patients*…